Ignite Creation Date:
2025-12-24 @ 4:48 PM
Ignite Modification Date:
2026-02-01 @ 4:00 AM
Study NCT ID:
NCT00442650
Status:
COMPLETED
Last Update Posted:
2016-11-21
First Post:
2007-02-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Moderate to Severe Psoriasis | View |
Keywords: